Lilly loses UK Alimta patent case, appeal planned
This article was originally published in Scrip
Executive Summary
A UK High Court has ruled against Eli Lilly in its fight to delay entry of generic competition for its blockbuster lung cancer drug Alimta (pemetrexed for injection).